Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 115 publications
Novel Immunotherapy Agents in Early-Phase Trials for Head and Neck Cancer.
Journal: JAMA network open
Published: July 16, 2026
Editor's Note: Essential Role of DNA Methyltransferase 1-mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 04, 2026
Dual Inhibition of TRIP13 and Aurora A Induces Mitotic DNA Damage and Concurrent Pyroptotic-Apoptotic Cell Death in Rb-Deficient Cancer Cells.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 15, 2025
NOTCH1 acts as a tumor suppressor that induces early differentiation in head and neck cancer.
Journal: JCI insight
Published: November 20, 2025
A Standardized Algorithm's Impact on Primary Detection in Head and Neck Carcinoma of Unknown Primary.
Journal: Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
Published: October 30, 2025
Advancing the development of TRIP13 inhibitors: A high-throughput screening approach.
Journal: SLAS discovery : advancing life sciences R & D
Published: February 23, 2025
Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting.
Journal: British journal of cancer
Published: February 13, 2025
Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting.
Journal: bioRxiv : the preprint server for biology
Published: January 27, 2025
Targeted inhibition of Aurora kinase A promotes immune checkpoint inhibition efficacy in human papillomavirus-driven cancers.
Journal: Journal for immunotherapy of cancer
Published: December 05, 2024
Polo-like kinase 1 inactivation enhances PI3K inhibition-mediated apoptosis of NOTCH1-mutant head and neck squamous cell carcinoma.
Journal: Cancer letters
Published: October 07, 2024
Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 18, 2024
Last Updated: 09/26/2026